Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Caterina Bartolacci is active.

Publication


Featured researches published by Caterina Bartolacci.


Biochemical Pharmacology | 2014

Sanguinarine suppresses basal-like breast cancer growth through dihydrofolate reductase inhibition

Cristina Kalogris; Chiara Garulli; Lucia Pietrella; Valentina Gambini; Stefania Pucciarelli; Cristiano Lucci; Martina Tilio; Maria Elexpuru Zabaleta; Caterina Bartolacci; Cristina Andreani; Mara Giangrossi; Manuela Iezzi; Barbara Belletti; Cristina Marchini; Augusto Amici

Basal-like breast cancer (BLBC) remains a great challenge because of its clinically aggressive nature and lack of effective targeted therapy. We analyzed the potential anti-neoplastic effects of sanguinarine, a natural benzophenanthridine alkaloid, against BLBC cells. Sanguinarine treatment resulted in a reduction of cell migration, in a dose-dependent inhibition of cell viability and in the induction of cell death by apoptosis in both human (MDA-MB-231 cells) and mouse (A17 cells) in vitro models of BLBC. In vivo experiments demonstrated that oral administration of sanguinarine reduced the development and growth of A17 transplantable tumors in FVB syngeneic mice. Western blotting analysis revealed that suppression of BLBC growth by sanguinarine was correlated with a concurrent upregulation of p27 and downregulation of cyclin D1 and with the inhibition of STAT3 activation. In addition, we identified sanguinarine as a potent inhibitor of dihydrofolate reductase (DHFR), able to impair enzyme activity even in methotrexate resistant MDA-MB-231 cells. These results provide evidence that sanguinarine is a promising anticancer drug for the treatment of BLBC.


Cellular Signalling | 2014

Dorsomorphin reverses the mesenchymal phenotype of breast cancer initiating cells by inhibition of bone morphogenetic protein signaling

Chiara Garulli; Cristina Kalogris; Lucia Pietrella; Caterina Bartolacci; Cristina Andreani; Maurizio Falconi; Cristina Marchini; Augusto Amici

Increasing evidence supports the theory that tumor growth, homeostasis, and recurrence are dependent on a small subset of cells with stem cell properties, redefined cancer initiating cells (CICs) or cancer stem cells. Bone morphogenetic proteins (BMPs) are involved in cell-fate specification during embryogenesis, in the maintenance of developmental potency in adult stem cells and may contribute to sustain CIC populations in breast carcinoma. Using the mouse A17 cell model previously related to mesenchymal cancer stem cells and displaying properties of CICs, we investigated the role of BMPs in the control of breast cancer cell plasticity. We showed that an autocrine activation of BMP signaling is crucial for the maintenance of mesenchymal stem cell phenotype and tumorigenic potential of A17 cells. Pharmacological inhibition of BMP signaling cascade by Dorsomorphin resulted in the acquisition of epithelial-like traits by A17 cells, including expression of Citokeratin-18 and E-cadherin, through downregulation of Snail and Slug transcriptional factors and Cyclooxygenase-2 (COX2) expression, and in the loss of their stem-features and self-renewal ability. This phenotypic switch compromised A17 cell motility, invasiveness and in vitro tumor growth. These results reveal that BMPs are key molecules at the crossroad between stemness and cancer.


Nanomedicine: Nanotechnology, Biology and Medicine | 2017

Manipulation of lipoplex concentration at the cell surface boosts transfection efficiency in hard-to-transfect cells

Sara Palchetti; Daniela Pozzi; Cristina Marchini; Augusto Amici; Cristina Andreani; Caterina Bartolacci; Luca Digiacomo; Valentina Gambini; Francesco Cardarelli; Carmine Di Rienzo; Giovanna Peruzzi; Heinz Amenitsch; Rocco Palermo; Isabella Screpanti; Giulio Caracciolo

To date, efficiency upon non-viral DNA delivery remains low and this implies the existence of unidentified transfection barriers. Here we explore the mechanisms of action of multicomponent (MC) cationic liposome/DNA complexes (lipoplexes) by a combination of reporter technologies, dynamic light scattering (DLS), synchrotron small angle X-ray scattering (SAXS), fluorescence activated cell sorting (FACS) analysis and laser scanning confocal microscopy (LSCM) in live cells. Lipofectamine - the gold standard among transfection reagents - was used as a reference. On the basis of our results, we suggest that an additional transfection barrier impairs transfection efficiency, that is: low lipoplex concentration at the cell surface. Based on the acquired knowledge we propose an optimized transfection protocol that allowed us to efficiently transfect DND41, JURKAT, MOLT3, P12-ICHIKAWA, ALL-SILL, TALL-1 human T-cell acute lymphoblastic leukemia (T-ALL) cell lines known to be difficult-to-transfect by using non-viral vectors and where LFN-based technologies fail to give satisfactory results.


Cancer Letters | 2016

Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib

Martina Tilio; Valentina Gambini; Junbiao Wang; Chiara Garulli; Cristina Kalogris; Cristina Andreani; Caterina Bartolacci; Maria Elexpuru Zabaleta; Lucia Pietrella; Albana Hysi; Manuela Iezzi; Barbara Belletti; Fiorenza Orlando; Mauro Provinciali; Roberta Galeazzi; Cristina Marchini; Augusto Amici

HER2 tyrosine kinase receptor is a validated target in breast cancer therapy. However, increasing evidence points to a major role of Δ16HER2 splice variant commonly coexpressed with HER2 and identified as a clinically important HER2 molecular alteration promoting aggressive metastatic breast cancer. Consistently, mice transgenic for the human Δ16HER2 isoform (Δ16HER2 mice) develop invasive mammary carcinomas with early onset and 100% penetrance. The present study provides preclinical evidence that Δ16HER2 expression confers de novo resistance to standard anti-HER2-therapies such as Lapatinib and acquired resistance to the selective Src inhibitor Saracatinib in breast cancer. Of note, Dacomitinib, an irreversible small molecule pan-HER inhibitor, was able to completely suppress Δ16HER2-driven breast carcinogenesis. Thus, only Dacomitinib may offer benefit in this molecularly defined patient subset by irreversibly inhibiting Δ16HER2 activation.


Aging | 2017

Resveratrol fuels HER2 and ERα-positive breast cancer behaving as proteasome inhibitor

Cristina Andreani; Caterina Bartolacci; Kathleen Wijnant; Rita Crinelli; Marzia Bianchi; Mauro Magnani; Albana Hysi; Manuela Iezzi; Augusto Amici; Cristina Marchini

The phytoestrogen resveratrol has been reported to possess cancer chemo-preventive activity on the basis of its effects on tumor cell lines and xenograft or carcinogen-inducible in vivo models. Here we investigated the effects of resveratrol on spontaneous mammary carcinogenesis using Δ16HER2 mice as HER2+/ERα+ breast cancer model. Instead of inhibiting tumor growth, resveratrol treatment (0.0001% in drinking water; daily intake of 4μg/mouse) shortened tumor latency and enhanced tumor multiplicity in Δ16HER2 mice. This in vivo tumor-promoting effect of resveratrol was associated with up-regulation of Δ16HER2 and down-regulation of ERα protein levels and was recapitulated in vitro by murine (CAM6) and human (BT474) tumor cell lines. Our results demonstrate that resveratrol, acting as a proteasome inhibitor, leads to Δ16HER2 accumulation which favors the formation of Δ16HER2/HER3 heterodimers. The consequential activation of downstream mTORC1/p70S6K/4EBP1 pathway triggers cancer growth and proliferation. This study provides evidence that resveratrol mechanism of action (and hence its effects) depends on the intrinsic molecular properties of the cancer model under investigation, exerting a tumor-promoting effect in luminal B breast cancer subtype models.


Oxidative Medicine and Cellular Longevity | 2018

Combination of Coenzyme Q10 Intake and Moderate Physical Activity Counteracts Mitochondrial Dysfunctions in a SAMP8 Mouse Model

Cristina Andreani; Caterina Bartolacci; Michele Guescini; Michela Battistelli; Vilberto Stocchi; F. Orlando; M. Provinciali; Augusto Amici; C. Marchini; Luca Tiano; Patrick Orlando; Sonia Silvestri

Aging skeletal muscles are characterized by a progressive decline in muscle mass and muscular strength. Such muscular dysfunctions are usually associated with structural and functional alterations of skeletal muscle mitochondria. The senescence-accelerated mouse-prone 8 (SAMP8) model, characterized by premature aging and high degree of oxidative stress, was used to investigate whether a combined intervention with mild physical exercise and ubiquinol supplementation was able to improve mitochondrial function and preserve skeletal muscle health during aging. 5-month-old SAMP8 mice, in a presarcopenia phase, have been randomly divided into 4 groups (n = 10): untreated controls and mice treated for two months with either physical exercise (0.5 km/h, on a 5% inclination, for 30 min, 5/7 days per week), ubiquinol 10 (500 mg/kg/day), or a combination of exercise and ubiquinol. Two months of physical exercise significantly increased mitochondrial damage in the muscles of exercised mice when compared to controls. On the contrary, ubiquinol and physical exercise combination significantly improved the overall status of the skeletal muscle, preserving mitochondrial ultrastructure and limiting mitochondrial depolarization induced by physical exercise alone. Accordingly, combination treatment while promoting mitochondrial biogenesis lowered autophagy and caspase 3-dependent apoptosis. In conclusion, the present study shows that ubiquinol supplementation counteracts the deleterious effects of physical exercise-derived ROS improving mitochondrial functionality in an oxidative stress model, such as SAMP8 in the presarcopenia phase.


Applied Physics Letters | 2015

Getting the most from gene delivery by repeated DNA transfections

Maura Montani; Cristina Marchini; Gretta Veronica Badillo Pazmay; Cristina Andreani; Caterina Bartolacci; Augusto Amici; Daniela Pozzi; Giulio Caracciolo

Intracellular delivery of reporter genes causes cells to be luminescent or fluorescent, this condition being of tremendous relevance in applied physics research. Potential applications range from the study of spatial distribution and dynamics of plasma membrane and cytosolic proteins up to the rational design of nanocarriers for gene therapy. Since efficiency of gene delivery is the main limit in most biophysical studies, versatile methods that can maximize gene expression are urgently needed. Here, we describe a robust methodology based on repeated gene delivery in mammalian cells. We find this procedure to be much more efficient than the more traditional route of gene delivery making it possible to get high-quality data without affecting cell viability. Implications for biophysical investigations are discussed.


Current Protein & Peptide Science | 2018

Walking a Tightrope: A Perspective of Resveratrol Effects on Breast Cancer.

Caterina Bartolacci; Cristina Andreani; Augusto Amici; Cristina Marchini


European Journal of Medicinal Chemistry | 2018

In vitro and in vivo studies of gold(I) azolate/phosphane complexes for the treatment of basal like breast cancer

Valentina Gambini; Martina Tilio; Eunice Wairimu Maina; Cristina Andreani; Caterina Bartolacci; Junbiao Wang; Manuela Iezzi; Stefano Ferraro; Anna Teresa Ramadori; Oumarou Camille Simon; Stefania Pucciarelli; Guojun Wu; Q. Ping Dou; Cristina Marchini; Rossana Galassi; Augusto Amici


Cancer immunology research | 2018

PHAGE-BASED ANTI-HER2 VACCINATION CAN CIRCUMVENT IMMUNE TOLERANCE AGAINST BREAST CANCER

Caterina Bartolacci; Cristina Andreani; Claudia Curcio; Sergio Occhipinti; Luca Massaccesi; Mirella Giovarelli; Roberta Galeazzi; Manuela Iezzi; Martina Tilio; Valentina Gambini; Junbiao Wang; Cristina Marchini; Augusto Amici

Collaboration


Dive into the Caterina Bartolacci's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Manuela Iezzi

University of Chieti-Pescara

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge